Target Prioritization
COMPUTATIONALMulti-criteria scoring across 7 dimensions: evidence strength, biological coherence, fragility relevance, interventionability, translational feasibility, novelty, and contradiction risk. Composite score determines Phase 3 priority.
▶How does Target Scoring work?
Each target receives a composite score from 8 independent dimensions, normalized 0–1 and combined via weighted average. Weights are transparent and reproducible (see the convergence engine).
Top 5 composite scores are Tier A (primary candidates), ranks 6–15 are Tier B (established modifiers), the remainder are Tier C (discovery).
46
Targets Scored
5
Tier A
10
Tier B
31
Tier C
60.5%
Top Score
46 / 46
| # | Symbol | Composite | Volume | Quality | Coherence | Independence | Intervention | Translation | Network | Novelty |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FGFR2 | 0.605 | 27 | 90 | 75 | 16 | 60 | 100 | 67 | 29 |
| 2 | IDH1 | 0.587 | 100 | 86 | 75 | 53 | 46 | 100 | 20 | 0 |
| 3 | BRAF | 0.559 | 1 | 81 | 33 | 2 | 69 | 100 | 67 | 64 |
| 4 | TP53 | 0.521 | 10 | 83 | 50 | 6 | 1 | 100 | 100 | 61 |
| 5 | ERBB2 | 0.503 | 1 | 80 | 42 | 3 | 30 | 100 | 60 | 63 |
| 6 | KRAS | 0.502 | 13 | 83 | 50 | 3 | 6 | 100 | 73 | 60 |
| 7 | IDH2 | 0.499 | 5 | 91 | 67 | 5 | 11 | 100 | 13 | 65 |
| 8 | ARID1A | 0.415 | 1 | 82 | 25 | 1 | 31 | 50 | 40 | 64 |
| 9 | BRCA1 | 0.405 | 1 | 87 | 25 | 1 | 0 | 50 | 67 | 66 |
| 10 | BAP1 | 0.383 | 1 | 69 | 33 | 1 | 4 | 100 | 13 | 60 |
| 11 | PIK3CA | 0.375 | 0 | 77 | 25 | 1 | 0 | 50 | 60 | 63 |
| 12 | IDH2 | 0.305 | 0 | 81 | 8 | 0 | 0 | 50 | 0 | 64 |
| 13 | IDH1 | 0.294 | 0 | 76 | 8 | 0 | 0 | 50 | 0 | 63 |
| 14 | TP53_363_393 | 0.275 | 0 | 89 | 8 | 3 | 0 | 0 | 0 | 67 |
| 15 | KDM6A_1080_1401 | 0.275 | 0 | 81 | 8 | 20 | 0 | 0 | 0 | 64 |
| 16 | IDH1_None_None | 0.271 | 0 | 88 | 8 | 1 | 0 | 0 | 0 | 66 |
| 17 | TET2_1135_1180 | 0.269 | 0 | 83 | 8 | 9 | 0 | 0 | 0 | 65 |
| 18 | DNMT3B_604_853 | 0.255 | 0 | 79 | 8 | 5 | 0 | 0 | 0 | 64 |
| 19 | TP53_1_62 | 0.244 | 0 | 75 | 8 | 3 | 0 | 0 | 0 | 62 |
| 20 | TP53_323_356 | 0.239 | 0 | 73 | 8 | 3 | 0 | 0 | 0 | 62 |
| 21 | IDH2_R140Q | 0.235 | 0 | 72 | 8 | 0 | 0 | 0 | 0 | 62 |
| 22 | TET2_catalytic | 0.196 | 0 | 54 | 8 | 2 | 0 | 0 | 0 | 56 |
| 23 | KDM6A | 0.190 | 1 | 50 | 8 | 6 | 0 | 0 | 0 | 55 |
| 24 | IDH1_R132H | 0.186 | 0 | 50 | 8 | 2 | 0 | 0 | 0 | 55 |
| 25 | HIF1A | 0.171 | 0 | 44 | 8 | 1 | 0 | 0 | 0 | 53 |
| 26 | CDKN2A | 0.170 | 0 | 0 | 0 | 0 | 0 | 50 | 67 | 40 |
| 27 | IDH1_WT | 0.170 | 0 | 43 | 8 | 1 | 0 | 0 | 0 | 53 |
| 28 | BRCA2 | 0.146 | 0 | 0 | 0 | 0 | 0 | 50 | 40 | 40 |
| 29 | NRAS | 0.120 | 0 | 0 | 0 | 0 | 0 | 0 | 67 | 40 |
| 30 | VHL | 0.110 | 0 | 0 | 0 | 0 | 0 | 50 | 0 | 40 |
| 31 | FH | 0.096 | 0 | 10 | 8 | 1 | 0 | 0 | 0 | 43 |
| 32 | PBRM1 | 0.090 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 40 |
| 33 | MDM2_17_125 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 34 | NRG1_176_246 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 35 | PAK1_74_149 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 36 | SMN1_260_294 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 37 | SMN1_90_159 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 38 | SRSF1_16_90 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 39 | TET2 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 40 | ATF3_None_None | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 41 | BCL2_None_None | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 42 | FUS_1_165 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 43 | FUS_471_526 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 44 | HNRNPA1_106_184 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 45 | HSPA1A_1_400 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| 46 | IGF1R_31_468 | 0.060 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |